![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Direxion Daily Financial Bull 3X Shares ETF
FAS
Ultra Financials Proshares
UYG
Spdr S&P Bank Etf
KBE
4
SPDR S&P Metals & Mining ETF
XME
5
SPDR S&P Retail ETF
XRT
US Stock MarketDetailed Quotes
Immuneering (IMRX)
- 5.530
- -0.210-3.66%
Trading Dec 17 15:41 ET
357.07MMarket Cap-3.09P/E (TTM)
5.790High5.450Low966.23KVolume5.720Open5.740Prev Close5.40MTurnover2.14%Turnover RatioLossP/E (Static)64.57MShares10.08052wk High1.57P/B250.29MFloat Cap1.10052wk Low--Dividend TTM45.26MShs Float33.990Historical High--Div Yield TTM5.92%Range %1.000Historical Low5.584Avg Price1Lot Size
IMRX Stock Chart
Real-Time
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
IMRX Orderflow
Unit: --
IMRX Orderflow Trend
IntradayDayWeekMonth
No Data
Immuneering (IMRX) News
Immuneering to Be Added to the Nasdaq Biotechnology Index (NBI)
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Immuneering Stock Down 13% But Insiders Still In US$514k Profit
We Think Immuneering (NASDAQ:IMRX) Can Afford To Drive Business Growth
Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock?
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
Immuneering (IMRX) Stock Forum
$Immuneering (IMRX.US)$ Recent analyst upgrade to target of $20. Hoping to see an upward push today...
$Immuneering (IMRX.US)$ insider added news soon
Morning Movers
Gapping Up
$PepGen (PEPG.US)$ soared 146.62% in premarket trading after reporting the highest mean splicing correction to date in DM1 patients in its FREEDOM DM1 phase 1 study.
$Evaxion A/S (EVAX.US)$ soared 36.97% in premarket trading after licensing its EVX B3 vaccine candidate to MSD for a 7.5 million cash payment and up to 592 million in milestone payments and royalties on sales.
$Lithium Americas (LAC.US)$ gai...
Gapping Up
$PepGen (PEPG.US)$ soared 146.62% in premarket trading after reporting the highest mean splicing correction to date in DM1 patients in its FREEDOM DM1 phase 1 study.
$Evaxion A/S (EVAX.US)$ soared 36.97% in premarket trading after licensing its EVX B3 vaccine candidate to MSD for a 7.5 million cash payment and up to 592 million in milestone payments and royalties on sales.
$Lithium Americas (LAC.US)$ gai...
8
4
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)